Literature DB >> 3734674

Somatomedin C/insulin-like growth factor I: simplified purification procedure and biological activities of the purified growth factor.

D J Morrell, K P Ray, A T Holder, A M Taylor, J A Blows, D J Hill, M Wallis, M A Preece.   

Abstract

Human somatomedin C has been purified from Cohn fraction IV paste by a simplified procedure using chromatofocusing, hydroxylapatite chromatography and reverse-phase high performance chromatography. The purified material has a specific activity by somatomedin C radioimmunoassay of 9160 units/mg (1 unit is defined as the amount of somatomedin present in 1 ml normal adult male human serum), representing a 650,000-fold purification, and possesses sulphation, mitogenic and insulin-like activities (specific activities of 3388 units/mg, 832 units insulin equivalents/mg and 1122 units/mg respectively). Somatomedin C is shown to be a potent stimulator of DNA synthesis (50% maximum stimulation at 150 fmol/ml) in isolated chondrocytes derived from costal cartilage, a major physiological target tissue.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734674     DOI: 10.1677/joe.0.1100151

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  4 in total

1.  Growth and endocrine function after renal transplantation.

Authors:  L Rees; S A Greene; P Adlard; J Jones; G B Haycock; S P Rigden; M Preece; C Chantler
Journal:  Arch Dis Child       Date:  1988-11       Impact factor: 3.791

2.  Longitudinal relation between limited joint mobility, height, insulin-like growth factor 1 levels, and risk of developing microalbuminuria: the Oxford Regional Prospective Study.

Authors:  R Amin; T K Bahu; B Widmer; R N Dalton; D B Dunger
Journal:  Arch Dis Child       Date:  2005-10       Impact factor: 3.791

3.  Growth and endocrine function in steroid sensitive nephrotic syndrome.

Authors:  L Rees; S A Greene; P Adlard; J Jones; G B Haycock; S P Rigden; M Preece; C Chantler
Journal:  Arch Dis Child       Date:  1988-05       Impact factor: 3.791

4.  Double blind placebo controlled trial of low dose oxandrolone in the treatment of boys with constitutional delay of growth and puberty.

Authors:  R Stanhope; C R Buchanan; G C Fenn; M A Preece
Journal:  Arch Dis Child       Date:  1988-05       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.